Drugs / Progesterone
Progesterone
also known as
Utrogestan · Crinone · Endometrin · micronized progesterone · Prometrium · Prolutex · Progestan · Cyclogest · +25 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | BIJUVA | vasomotor symptoms due to menopause | 2021-05-25 | “submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”).” therapeuticsmd.com ↗ |
| Label expansion | US (FDA) | PROGESTERONE | — | 2001-09-17 | fda.gov ↗ |
| Approved | US (FDA) | PROGESTERONE | — | 1974-11-01 | fda.gov ↗ |
Trials 196 · started per year
today
US approved 1974
1
1
1
2
1
3
3
2
4
4
7
5
9
7
5
12
9
7
9
9
10
8
10
9
10
9
6
8
2
9
12
1
19741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials · 1 missed | ||||||
| Phase 0 | NCT06616077 | Jun 2022 → Apr 2023 | endometrial disorder, progesterone resistance | Reproductive Health Research Insritute, Chile | Completed | No outcome recorded |
| Phase 0 | NCT05091866 | Apr 2022 → Dec 2024 | gliosarcoma | Emory University | Terminated | No outcome recorded |
| Phase 0 | NCT04104984 | Feb 2020 → Sep 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03687021 | Oct 2018 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02486757 | Apr 2015 → Mar 2016 | menstrual disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT01483365 | Dec 2011 → Dec 2014 | menstrual disorder | Wolfson Medical Center | Unknown | Missed primary |
| Phase 0 | NCT00929006 | Jun 2008 → Oct 2025 overdue | — | University of Virginia | Recruiting | Mixed |
| Phase 118 trials · 1 met primary | ||||||
| Phase 1 | NCT06668896 | Sep 2026 → Nov 2027 expected | — | Daré Bioscience, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05980091 | Sep 2023 → Dec 2026 | female infertility | ART Fertility Clinics LLC | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05969795 | Sep 2023 → Apr 2026 overdue | female infertility, pregnancy disorder | ART Fertility Clinics LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05678192 | Dec 2021 → Mar 2023 | — | Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT05418426 | Aug 2020 → Apr 2021 | postmenopausal atrophic vaginitis | Daré Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04365127 | Apr → Aug 2020 | COVID-19 | Sara Ghandehari | Completed | Met primary |
| Phase 1 | NCT03737656 | Nov 2018 → May 2019 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03340701 | Nov 2017 → Jun 2018 | — | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT02272647 | Dec 2014 → Dec 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01602679 | May 2012 → Jul 2015 | — | University of Virginia | Terminated | No outcome recorded |
| Phase 1 | NCT01428089 | Mar 2011 → Dec 2024 | polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| Phase 1 | NCT01293747 | Feb → Aug 2011 | — | Productos Científicos S. A. de C. V. | Completed | No outcome recorded |
| Phase 1 | NCT01176175 | Aug → Dec 2010 | infertility disorder | Productos Científicos S. A. de C. V. | Completed | No outcome recorded |
| Phase 1 | NCT00864214 | Jun 2008 → Dec 2009 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00594217 | Nov 2007 → Jan 2020 | polycystic ovary syndrome | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00377923 | Aug 2005 → Mar 2006 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 1 | NCT01773772 | Feb 2005 → Jun 2009 | — | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00001259 | Aug 1992 → Feb 2020 | premenstrual tension | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03774745 | Feb → Jul 2019 | — | University of California, Davis | Terminated | No outcome recorded |
| Phase 1/2 | NCT01057511 | Dec 2009 → Aug 2011 | — | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01147770 | Sep 2008 → Jan 2010 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
| Phase 1/2 | NCT00048646 | May 2002 → Sep 2005 | traumatic brain injury | David Wright | Completed | No outcome recorded |
| Phase 1/2 | NCT00001322 | Jun 1994 → Mar 2020 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 230 trials · 2 met primary · 3 missed | ||||||
| Phase 2 | NCT07436793 | Jun 2026 → Jun 2030 expected | endometrial disorder, endometrial endometrioid adenocarcinoma | New Mexico Cancer Research Alliance | Recruiting | No outcome recorded |
| Phase 2 | NCT06807580 | May 2025 → Feb 2027 expected | — | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT05982470 | Aug 2023 → Jun 2025 | cerebrovascular disorder, cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04865029 | Jul 2021 → Jan 2022 | COVID-19 | Tulane University | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04938011 | Jul 2021 → Jun 2023 | infertility disorder | Nanjing University | Unknown | No outcome recorded |
| Phase 2 | NCT04645446 | Feb 2021 → Oct 2022 | dry eye syndrome | SIFI SpA | Completed | No outcome recorded |
| Phase 2 | NCT03990051 | Oct 2019 → Oct 2021 | chronic graft versus host disease | Glia, LLC | Completed | Met primary |
| Phase 2 | NCT03701490 | Mar 2019 → Sep 2022 | infertility disorder | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 2 | NCT03729869 | Jan 2019 → Nov 2022 | substance-related disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT03906669 | Mar 2018 → Apr 2024 | female breast carcinoma, hormone receptor-positive breast cancer | St Vincent's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02460302 | Dec 2016 → Dec 2020 | postmenopausal atrophic vaginitis | Mount Sinai Hospital, Canada | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02841137 | Jun 2016 → Aug 2017 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 2 | NCT02400021 | Aug 2015 → Dec 2016 | HIV infectious disease | Mount Sinai Hospital, Canada | Unknown | No outcome recorded |
| Phase 2 | NCT02145767 | Dec 2014 → Feb 2021 | pregnancy disorder with abortive outcome | Sir Mortimer B. Davis - Jewish General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02133573 | Jul 2014 → Nov 2021 | congenital heart disease, developmental disability, periventricular leukomalacia | Children's Hospital of Philadelphia | Completed | Missed primary |
| Phase 2 | NCT01972464 | Nov 2013 → Aug 2016 | nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02225353 | Sep 2013 → Mar 2017 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01929083 | Apr 2013 → Jun 2014 | long QT syndrome | Indiana University | Completed | Met primary |
| Phase 2 | NCT01811225 | Dec 2012 → Jun 2017 | nicotine dependence | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01126255 | Mar 2011 → Jul 2014 | vulvar lichen sclerosus | Insel Gruppe AG, University Hospital Bern | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT00919919 | Jun 2009 → Sep 2010 | endometrial cancer | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00866437 | Apr 2009 → May 2010 | premenstrual tension | EVE Medical Systems Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT00302731 | Feb 2006 → Jan 2014 | premature menopause | Jeanne Drisko, MD, CNS, FACN | Terminated | No outcome recorded |
| Phase 2 | NCT01153581 | Feb 2006 → Dec 2012 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00152438 | Sep 2005 → Oct 2009 | — | University of British Columbia | Unknown | No outcome recorded |
| Phase 2 | NCT00247169 | Aug 2004 → Apr 2009 | cervical intraepithelial neoplasia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT02033512 | Jan 2003 → Jan 2004 | — | University Potiguar | Completed | No outcome recorded |
| Phase 2 | NCT00005108 | Apr 2000 → Jan 2002 | atherosclerosis | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00000295 | Apr 1999 → Dec 2001 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00001481 | Apr 1996 → Oct 2024 | postpartum depression | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/36 trials · 1 met primary | ||||||
| Phase 2/3 | NCT06530459 | Aug 2024 → Apr 2027 expected | arthropathy, menstrual disorder | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02187224 | Sep 2016 → Sep 2021 | alcohol dependence, post-traumatic stress disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT01308814 | Oct 2010 → Mar 2016 | depressive disorder | University of North Carolina, Chapel Hill | Completed | Met primary |
| Phase 2/3 | NCT00928213 | Aug 2009 → Dec 2010 | preeclampsia | Ben-Gurion University of the Negev | Unknown | No outcome recorded |
| Phase 2/3 | NCT00632099 | Feb 2008 → Sep 2012 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00775242 | Apr 2007 → Nov 2008 | — | Centro A.F. de Estudios Tecnologicos, S.A. | Completed | No outcome recorded |
| Phase 334 trials · 4 met primary · 2 missed | ||||||
| Phase 3 | NCT07613528 | Mar 2027 → Sep 2029 expected | pregnancy disorder | University Hospital, Montpellier | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07796737 | Dec 2026 → Dec 2029 expected | pregnancy loss, recurrent, 4 | General University Hospital, Prague | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06851754 | Jul 2025 → Dec 2031 expected | primary ovarian failure | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | No outcome recorded |
| Phase 3 | NCT06644794 | Mar 2025 → Sep 2027 expected | female infertility | Shandong University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05899010 | Jul 2023 → Jun 2027 expected | infertility disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 3 | NCT04549116 | Oct 2022 → Jan 2026 overdue | infertility disorder | IBSA Institut Biochimique SA | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04806919 | Apr 2021 → Feb 2025 | pregnancy loss, recurrent, 4 | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 3 | NCT03540225 | Apr 2020 → Apr 2022 | pregnancy disorder | Chiu Yee Liona Poon | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03565211 | Jul 2018 → Jul 2019 | — | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02633878 | Oct 2017 → Oct 2025 | — | Heilongjiang University of Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03309709 | Oct 2017 → Oct 2019 | endometrial polyp | University Magna Graecia | Unknown | No outcome recorded |
| Phase 3 | NCT03202186 | Aug 2017 → Dec 2018 | — | BHR Pharma, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02950948 | May 2017 → Mar 2019 | — | IBSA Institut Biochimique SA | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02950935 | Apr 2017 → May 2018 | pregnancy disorder | IBSA Institut Biochimique SA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02793908 | Jun 2016 → Jun 2017 | endometriosis | University Magna Graecia | Unknown | No outcome recorded |
| Phase 3 | NCT02922348 | Mar 2016 → Dec 2018 | primary ovarian failure | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 3 | NCT02224313 | Dec 2015 → Aug 2018 | — | Intira Sriprasert | Completed | No outcome recorded |
| Phase 3 | NCT02798653 | Nov 2015 → Nov 2019 | infertility disorder | Royan Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02491437 | Jul 2015 → May 2017 | female infertility | Abbott | Completed | Met primary |
| Phase 3 | NCT02779582 | Jun 2015 → Jun 2018 | dysmenorrhea, premature menopause | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT02304237 | Dec 2014 → Nov 2016 | — | Ewha Womans University Mokdong Hospital | Unknown | Met primary |
| Phase 3 | NCT01941875 | Jul 2014 → Sep 2016 | infertility disorder | University of Alberta | Completed | No outcome recorded |
| Phase 3 | NCT01942668 | Aug 2013 → Oct 2016 | — | TherapeuticsMD | Completed | Mixed |
| Phase 3 | NCT01464697 | Oct 2011 → Jun 2018 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00822900 | Mar 2010 → May 2014 | traumatic brain injury | David Wright | Terminated | Missed primary |
| Phase 3 | NCT00946192 | May 2009 → Feb 2020 | functional hypothalamic amenorrhea | Massachusetts General Hospital | Completed | Met primary |
| Phase 3 | NCT00615251 | Feb 2008 → Aug 2009 | infertility disorder | Duramed Research | Completed | No outcome recorded |
| Phase 3 | NCT01180296 | Nov 2006 → Jan 2009 | — | Fetal Medicine Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00536003 | Jul 2006 → Dec 2012 | — | begoña Martinez de Tejada | Terminated | Missed primary |
| Phase 3 | NCT00480402 | Jan 2006 → Jun 2007 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 3 | NCT00029536 | Oct 2000 → Jun 2010 | epilepsy | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00000555 | Aug 1996 → May 2003 | coronary atherosclerosis, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000466 | Sep 1987 → Oct 2000 | coronary artery disorder, diabetes mellitus, hyperlipoproteinemia, hypertensive disorder +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000176 | ? → Sep 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 458 trials · 2 met primary · 8 missed | ||||||
| Phase 4 | NCT07818278 | Oct 2026 → Aug 2029 expected | infertility disorder | University Hospital, Ghent | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07508657 | Aug 2026 → Jun 2029 expected | infertility disorder | Kirstine Kirkegaard | Recruiting | No outcome recorded |
| Phase 4 | NCT07448597 | Aug 2026 → May 2028 expected | preeclampsia | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07466199 | Jul → Aug 2026 overdue | ovarian dysfunction | Instituto Valenciano de Infertilidade de Lisboa | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06497894 | Jan → Jul 2026 overdue | insomnia | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 4 | NCT07350317 | Jan → Dec 2026 expected | — | Trust Fertility Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07649668 | Nov 2025 → May 2026 | — | Dr Mudassar Saeed Pansota | Completed | No outcome recorded |
| Phase 4 | NCT06306404 | Oct 2025 → Oct 2029 expected | insomnia | VU University of Amsterdam | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07865949 | Aug 2025 → Jan 2026 | — | Medicare Hospital (Pvt) Limited | Completed | No outcome recorded |
| Phase 4 | NCT07523295 | May → Nov 2025 | — | Medicare Hospital (Pvt) Limited | Completed | No outcome recorded |
| Phase 4 | NCT06610305 | Sep 2024 → Jun 2028 expected | major depressive disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT05954962 | Dec 2023 → Apr 2025 | — | Instituto Bernabeu | Completed | No outcome recorded |
| Phase 4 | NCT05787509 | Apr 2023 → Apr 2029 expected | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT05080569 | Mar 2023 → Dec 2025 overdue | infertility disorder, pregnancy disorder | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 4 | NCT04499131 | Dec 2021 → Apr 2025 | female infertility | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT04675788 | Sep 2021 → Apr 2025 | long QT syndrome | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT05061641 | May 2021 → Jun 2022 | — | Caixia Liu | Unknown | No outcome recorded |
| Phase 4 | NCT04725864 | May 2021 → Jun 2025 | infertility disorder | Vastra Gotaland Region | Unknown | No outcome recorded |
| Phase 4 | NCT04112368 | Sep 2020 → Aug 2024 | — | University of Illinois at Chicago | Completed | Met primary |
| Phase 4 | NCT04507022 | Aug 2020 → Feb 2021 | female infertility, male infertility | Rahem Fertility Center | Completed | No outcome recorded |
| Phase 4 | NCT04190927 | Jun 2020 → Jun 2023 | menstrual disorder | Women's Hormone Network | Unknown | No outcome recorded |
| Phase 4 | NCT04143880 | Feb → Oct 2020 | stroke disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04140968 | Nov 2019 → May 2021 | — | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03858049 | May 2019 → Oct 2021 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 4 | NCT03834883 | Mar 2019 → May 2024 | long QT syndrome | Indiana University | Completed | Mixed |
| Phase 4 | NCT02430233 | Dec 2018 → Feb 2023 | — | HaEmek Medical Center, Israel | Completed | Missed primary |
| Phase 4 | NCT03619707 | Aug 2018 → Aug 2021 | infertility disorder | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03498313 | Jul 2018 → May 2021 | — | University of Illinois at Chicago | Completed | Mixed |
| Phase 4 | NCT03930212 | Jan → Dec 2018 | pregnancy disorder, progesterone resistance | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT03343795 | Jul 2017 → May 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03720847 | Dec 2016 → Nov 2017 | — | University of North Carolina, Chapel Hill | Completed | Met primary |
| Phase 4 | NCT02913495 | Sep 2016 → Aug 2021 | — | Thomas Jefferson University | Completed | Missed primary |
| Phase 4 | NCT02513940 | May 2016 → Oct 2017 | long QT syndrome | Indiana University | Completed | Mixed |
| Phase 4 | NCT02685072 | Apr 2016 → Dec 2017 | — | Yale University | Completed | Missed primary |
| Phase 4 | NCT03040830 | Nov 2015 → Oct 2016 | — | Mansoura Integrated Fertility Center | Completed | Mixed |
| Phase 4 | NCT02567552 | May → Dec 2015 | — | IVI Barcelona | Completed | Missed primary |
| Phase 4 | NCT02363127 | Feb 2015 → Oct 2016 | infertility disorder | Instituto Bernabeu | Completed | No outcome recorded |
| Phase 4 | NCT02254577 | Oct 2014 → Apr 2018 | female infertility | Shady Grove Fertility Reproductive Science Center | Completed | Mixed |
| Phase 4 | NCT02372942 | Feb 2014 → Nov 2019 | — | University of Padova | Unknown | No outcome recorded |
| Phase 4 | NCT01927029 | Aug 2013 → Oct 2014 | — | Universidad del Desarrollo | Unknown | No outcome recorded |
| Phase 4 | NCT01809639 | Jun 2013 → Dec 2015 | traumatic encephalopathy | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 4 | NCT01940653 | Nov 2012 → Dec 2017 | — | University Hospital Brussels | Completed | Missed primary |
| Phase 4 | NCT02032797 | Nov 2012 → Sep 2019 | — | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT01643980 | Aug 2012 → Mar 2016 | — | Dra.Cristina Martinez Payo | Completed | Missed primary |
| Phase 4 | NCT01237535 | Nov 2011 → Nov 2013 | male infertility | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01500863 | Nov 2011 → May 2012 | ovarian hyperstimulation syndrome | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT01826747 | Apr 2011 → Jan 2015 | infertility disorder | Universitaire Ziekenhuizen KU Leuven | Completed | Missed primary |
| Phase 4 | NCT01286246 | Jan 2011 → Oct 2014 | obstetric disorder | University of Calgary | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01010048 | Oct 2009 | urolithiasis | Chongqing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02618148 | Jan 2009 → Jun 2015 | — | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00802360 | Dec 2008 → Nov 2009 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01123538 | Dec 2008 → Oct 2011 | — | University Hospital of North Norway | Unknown | No outcome recorded |
| Phase 4 | NCT01698164 | Dec 2008 → Oct 2012 | breast cancer, cardiovascular disorder, osteoporosis, premature menopause | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01959464 | Nov 2008 → Sep 2010 | infertility disorder, pregnancy disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00345306 | Mar 2007 → ? | — | Hadassah Medical Organization | Suspended | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00160199 | Nov 2004 → Feb 2009 | secondary amenorrhea | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00530582 | Nov 2003 → Jul 2004 | — | Max-Planck-Institute of Psychiatry | Completed | No outcome recorded |
| Phase 4 | NCT00732693 | Feb 2002 → Nov 2006 | primary ovarian failure | University of Edinburgh | Completed | Mixed |
| Phase not applicable38 trials · 6 missed | ||||||
| — | NCT07620587 | Jun 2026 → Aug 2028 expected | — | Wilfrid Laurier University | Recruiting | No outcome recorded |
| — | NCT07372495 | Apr 2026 → Dec 2028 expected | preterm premature rupture of the membranes | National Hospital of Obstetrics and Gynecology | Recruiting | No outcome recorded |
| — | NCT07568574 | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07003373 | Jul 2025 → Jul 2026 overdue | — | Malihe Mahmoudinia | Not yet recruiting | No outcome recorded |
| — | NCT06928844 | Apr → Aug 2025 overdue | — | The General Authority for Teaching Hospitals and Institutes | Recruiting | No outcome recorded |
| — | NCT06005207 | Aug 2023 → Dec 2024 | female infertility | Nanjing University | Unknown | No outcome recorded |
| — | NCT05232344 | Apr 2022 → Feb 2024 | infertility disorder | University Hospital, Montpellier | Completed | Missed primary |
| — | NCT05276531 | Apr → Jun 2022 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT05312190 | Mar → Dec 2022 | menstrual disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04161989 | May 2020 → Jun 2022 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| — | NCT04248309 | Mar 2020 → Mar 2021 | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT05189145 | Oct 2019 → Mar 2021 | female infertility | Alexandria University | Completed | No outcome recorded |
| — | NCT03992937 | Jun 2019 → Dec 2020 | endometrial hyperplasia without atypia | Kocaeli University | Completed | Missed primary |
| — | NCT03740568 | Nov 2018 → Feb 2020 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| — | NCT03504345 | May 2018 → Apr 2019 | infertility disorder | Mount Sinai Hospital, Canada | Unknown | No outcome recorded |
| — | NCT03202836 | Jun 2017 → Jul 2018 | — | Chulalongkorn University | Completed | Missed primary |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT05062135 | Feb → Sep 2014 | polycystic ovary syndrome, progesterone resistance | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT03088046 | Feb 2014 → Feb 2015 | anovulation, polycystic ovary syndrome | Fundacion Dexeus | Completed | No outcome recorded |
| — | NCT01762943 | Aug 2013 → Oct 2016 | postpartum depression | University of North Carolina, Chapel Hill | Completed | Missed primary |
| — | NCT01744574 | Dec 2012 → Jul 2017 | nicotine dependence | University of Minnesota | Completed | No outcome recorded |
| — | NCT01523483 | Mar 2012 → Mar 2015 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT01546454 | Feb → Jun 2012 | coronary artery disorder | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT01780610 | Jan 2012 → Jan 2015 | infertility disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01406197 | Jul 2011 → Oct 2013 | — | St. Joseph's Hospital and Medical Center, Phoenix | Withdrawn | No outcome recorded |
| — | NCT01428245 | Apr 2011 → May 2013 | polycystic ovary syndrome | University of Virginia | Terminated | No outcome recorded |
| — | NCT01249274 | Feb 2011 → Jul 2013 | cocaine abuse, cocaine dependence | Yale University | Completed | Mixed |
| — | NCT01206998 | Jul → Aug 2010 | — | University of Rochester | Withdrawn | No outcome recorded |
| — | NCT01780558 | Jan 2010 → Jan 2015 | infertility disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT00805207 | Sep 2007 → Mar 2013 | obesity disorder, obstructive sleep apnea syndrome, polycystic ovary syndrome | Washington University School of Medicine | Completed | Missed primary |
| — | NCT00579553 | Oct 2006 → May 2011 | — | University of Oklahoma | Completed | Missed primary |
| — | NCT01428193 | Sep 2006 → Aug 2017 | polycystic ovary syndrome | University of Virginia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00676026 | May 2005 → Feb 2009 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00565916 | Aug 2004 → Jan 2008 | — | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT00700492 | May 2004 → Mar 2008 | infertility disorder | University Hospital, Gasthuisberg | Terminated | No outcome recorded |
| — | NCT00079248 | Mar 2002 → ? | breast cancer, osteoporosis | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| — | NCT01425541 | Apr 2000 → Aug 2025 | polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| — | NCT00329316 | — | pregnancy disorder | The Baruch Padeh Medical Center, Poriya | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy180 trials | ||||||
| Phase 0 | NCT06870266 Comparator | Mar 2025 → Mar 2027 expected | — | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05128071 Comparator | Feb 2022 → May 2024 | methamphetamine dependence | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04426487 Comparator | Jun → Sep 2020 | traumatic brain injury | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT04046185 Comparator | Oct 2019 → Oct 2021 | uterine carcinoma | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03430050 Comparator | Oct 2017 → Apr 2018 | cannabis dependence, substance withdrawal syndrome | Medical University of South Carolina | Completed | No outcome recorded |
| Show all 180 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg glenmarkpharma.com ↗ |
| 2025-09-30 | Xiromed LLC | Regulatory Xiromed LLC Announces Approval and Launch of First-to-Market Generic Progesterone Vaginal Insert 100mg xiromed.com ↗
Xiromed’s Abbreviated New Drug Application (ANDA) approval is the first generic approved by the U.S. Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation and is eligible for 180-day CGT market exclusivity. |
| 2024-06-28 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® Approved genscigroup.com ↗
GenSci recently announced that its Jin Sai Xin® progesterone injection (II) (hereafter referred to as Jin Sai Xin), has received approval from the National Medical Products Administration (NMPA) of China. |
| 2021-05-25 | TherapeuticsMD | Regulatory TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA therapeuticsmd.com ↗
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”). |
| 2021-04-08 | TherapeuticsMD | Regulatory TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium therapeuticsmd.com ↗
“The approval of BIJUVE in the UK and BIJUVA in Belgium marks a significant accomplishment by Theramex that offers a new treatment option to post-menopausal women,” |
| 2021-03-26 | Covis Pharma S.à.r.l. | Results EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies covispharma.com ↗
Covis Group S.à r.l. (“Covis”) announced today that the updated results of EPPPIC (Evaluating Progestogens for Preventing Preterm birth International Collaborative), found that both 17-OHPC and vaginal progesterone reduced the relative risk of early preterm birth in high-risk singleton pregnancies before 34 weeks, while current evidence for oral progesterone is insufficient to support use. |
| 2021-03-25 | IBSA Institut Biochimique SA | Results IBSA supports a pilot trial for the treatment of SARS-CoV-2 ibsagroup.com ↗
The results confirm the protective role of a subcutaneous formulation of progesterone in male patients with COVID-19. |
| 2020-09-21 | TherapeuticsMD | Regulatory Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA® therapeuticsmd.com ↗
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. |
| 2020-02-03 | TherapeuticsMD | Regulatory TherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA® therapeuticsmd.com ↗
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today that it submitted a New Drug Application prior-approval efficacy supplement for BIJUVA 0.5 mg/100 mg (estradiol and progesterone) capsules to the U.S. Food and Drug Administration (FDA) late January 2020. |
| 2019-11-26 | TherapeuticsMD | Regulatory Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada therapeuticsmd.com ↗
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for BIJUVA® has been accepted for review by Health Canada. |
| 2019-09-24 | TherapeuticsMD | Results TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society therapeuticsmd.com ↗
We are excited to report results from the REPLENISH Phase 3 trial for BIJUVA that show improvements in several sleep parameters, including sleep disturbances, in menopausal women with moderate to severe vasomotor symptoms taking BIJUVA as compared to placebo. |
| 2019-05-03 | TherapeuticsMD | Results TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting therapeuticsmd.com ↗
Data from the REPLENISH Phase 3 trial for BIJUVA showed significant improvement in the frequency and severity of vasomotor symptoms, regardless of the number and severity of hot flushes at baseline. |
| 2019-03-25 | TherapeuticsMD | Results TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting therapeuticsmd.com ↗
Data from the REPLENISH Phase 3 trial for BIJUVA showed improvements in hot flushes, night sweats, sweating, and quality of sleep. |
| 2019-03-08 | TherapeuticsMD | Results TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting therapeuticsmd.com ↗ |
| 2018-10-29 | TherapeuticsMD | Regulatory TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause therapeuticsmd.com ↗
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical* hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. |
| 2018-03-08 | TherapeuticsMD | Regulatory TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR therapeuticsmd.com ↗
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the acceptance of the NDA for TX-001HR by the U.S. Food and Drug Administration (FDA). |
| 2017-12-28 | TherapeuticsMD | Regulatory TherapeuticsMD Announces Submission of New Drug Application for TX-001HR therapeuticsmd.com ↗
announced today that it has submitted the New Drug Application (NDA) for TX-001HR |
| 2017-04-03 | TherapeuticsMD | Results TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017 therapeuticsmd.com ↗
The positive results of the pivotal phase 3 Replenish Trial data were featured in an oral and a poster presentation. |
| 2016-12-05 | TherapeuticsMD | Results TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR therapeuticsmd.com ↗
TX-001HR, the first bio-identical combination therapy of estradiol and progesterone evaluated in a randomized, controlled clinical trial met all co-primary efficacy and safety endpoints at multiple doses |
All press releases naming this drug 30 releases
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 381 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | progesterone | “The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg...” NCT02793908 ↗362“PURPOSE: To verify sufficient progesterone supplementation during the luteal phase and to determine the efficacy and safety of a natural micronized progesterone vaginal tablet...” PMID 26457065 ↗ Jun 2015 “Patients with low serum progesterone will be randomized to receive extra progesterone supplementation in the form of either: * Group A: oral 10 mg dydrogesterone (Duphaston®,...” NCT05758064 ↗ “In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and...” NCT02033512 ↗ “Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst...” NCT04806919 ↗ “Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8%...” NCT00656201 ↗ “Patients in the control group will receive artificial cycle therapy post-IVF-ET: progesterone injection 40 mg/day, or oral dydrogesterone tablets (Duphaston) 20 mg/day, or...” NCT07409792 ↗ “Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1...” NCT06497894 ↗ “This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT...” NCT06306404 ↗ “for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied” NCT01590173 ↗ “100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.” NCT00802360 ↗ |
| Known as | Amelgen | “Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst...” NCT04806919 ↗ |
| Known as | BHR401 | “The primary objective of the clinical trial is to demonstrate superiority of BHR401 (oral micronized progesterone) versus placebo as a monotherapy for moderate to severe VMS in...” NCT03202186 ↗ |
| Known as | Callavid | “400mg progesterone Callavid, 2 hour wear, twice daily for 7 days” NCT07136922 ↗ |
| Known as | Crinone | “The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg...” NCT02793908 ↗10“To compare the safety, efficacy, and tolerability of subcutaneous progesterone (Prolutex, 25 mg; IBSA Institut Biochimique SA) with vaginal progesterone gel (Crinone, 8%; Merck...” PMID 24140033 ↗ Oct 2013 “vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase” NCT01504139 ↗ “Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)” NCT01237535 ↗ “Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg” NCT01943812 ↗ “luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle” NCT02492451 ↗ “Luteal support with daily progesterone gel = Crinone 8%” NCT02048891 ↗ “crinone (progesterone 8%, vaginal application)” NCT01826747 ↗ “Progesterone Vaginal Gel [Crinone]” NCT04124913 ↗ |
| Known as | Cyclogest | “Vaginal progesterone (Cyclogest) 400 mg administered twice daily starting the day after insemination.” NCT07508657 ↗1“Cyclogest 400 mg pessary, twice daily for 7 days” NCT07136922 ↗ |
| Known as | Cyclogest 400mg | “400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, within two days after cerclage...” NCT03863613 ↗ |
| Known as | Endometrin | “Endometrin® (vaginal micronized progesterone tablets) supplemented by intramuscular injection of progesterone in oil (PIO) work as well as PIO alone for women undergoing...” NCT02254577 ↗9“Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan” NCT00345306 ↗ “Participants receive 100 mg vaginal progesterone inserts (e.g., Endometrin) administered twice daily.” NCT07319715 ↗ “vaginal progesterone - 100 mg Endometrin twice daily until week 8 of pregnancy.” NCT05838105 ↗ “micronized progesterone (Endometrin, Ferring Pharmaceuticals)” NCT01465373 ↗ “Luteal support: Endometrin 100mg vaginally three times daily” NCT01204840 ↗ “Vaginal Micronized Progesterone Tablet (Endometrin®)” NCT00296478 ↗ |
| Known as | FE 999913 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01710514 ↗ |
| Known as | medroxyprogesterone acetate | “Possible side effects of progesterone (medroxyprogesterone acetate) include; nausea, breast tenderness, changes to liver enzymes, blood clotting profile changes, acne and...” NCT00206544 ↗ |
| Known as | micronised progesterone | “Oestradiol cypionate intramuscular (IM) and micronised progesterone oral (PO), in addition to SOC” PMID 34848523 ↗ Nov 2021 |
| Known as | micronized progesterone | “In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a...” NCT07436793 ↗8“We will evaluate the efficacy and safety of Chinese herbal medicine (New "Shoutai Wan", NSTW) and/or oral micronized progesterone (OP) for treating threatened miscarriage in this trial.” NCT02633878 ↗ “Oral micronized progesterone will be added (100 mg/day for 12 days/month) in the event of spontaneous vaginal bleeding and/or at 12 months over the 2-year protocol.” NCT06851754 ↗ “Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course” NCT03088046 ↗ “Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.” NCT01308814 ↗ “micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily” NCT01269450 ↗ “estradiol plus micronized progesterone 200 mg daily for women with an intact uterus” NCT00005108 ↗ “cyclic micronized progesterone (MP), 200 milligrams per day for 12 days a month” NCT00000466 ↗ “Drug: Micronized Progesterone” NCT06856174 ↗ |
| Known as | Natural micronized progesterone | “Natural micronized progesterone, 400 mg/12 hours vaginal administration” NCT01353846 ↗ |
| Known as | natural progesterone | “Twenty-five women will be randomized to self-administer natural progesterone (Prometrium, 200 mg) vaginally every night starting between gestational week 16 and 24 until week 36” PMID 27965866 ↗ Aug 2016 |
| Known as | OHP17 | “Progesterone (OHP17)” NCT00830765 ↗ |
| Known as | OMP | “vaginal micronized progesterone (OMP), administered for the induction of withdrawal bleeding” NCT03088046 ↗ |
| Known as | Oral micronized progesterone | “Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone.” NCT01464697 ↗ |
| Known as | Oral micronized progesterone: Prometrium, Uteroestan | “Oral micronized progesterone: Prometrium®, Uteroestan®” NCT00152438 ↗ |
| Known as | Oral Progesterone | “Chinese Herbal Medicine (New "Shoutai Wan", one pack twice daily) + Oral Progesterone (100 mg thrice daily)” NCT02633878 ↗ |
| Known as | Pleyris | “The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg...” NCT02793908 ↗1“Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).” NCT03734770 ↗ |
| Known as | Pro-ocular | “Pro-ocular™ 1% Progesterone EP topical gel” NCT04645446 ↗ |
| Known as | Progeffik | “Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).” NCT03734770 ↗1“Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone (Progeffik)” NCT03701490 ↗ |
| Known as | Progestan | “Vaginal progesterone treatment with PROGESTAN® (200 mg 3 times daily) will be continued for 4 days after initiation of the investigational medicinal product (Day 1 to Day 4),...” NCT07613528 ↗2“After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg,...” NCT05232344 ↗ “progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.” NCT03948022 ↗ |
| Known as | Progesterone (prometrium, progestin) | “Progesterone (prometrium, progestin)” NCT02969590 ↗ |
| Known as | progesterone (Utrogestan, Besins International, France) | “progesterone (Utrogestan®, Besins International, France)” NCT01940653 ↗ |
| Known as | Progesterone in Oil (PIO) | “Endometrin® (vaginal micronized progesterone tablets) supplemented by intramuscular injection of progesterone in oil (PIO) work as well as PIO alone for women undergoing...” NCT02254577 ↗ |
| Known as | Prolutex | “To compare the safety, efficacy, and tolerability of subcutaneous progesterone (Prolutex, 25 mg; IBSA Institut Biochimique SA) with vaginal progesterone gel (Crinone, 8%; Merck...” PMID 24140033 ↗ Oct 20134“Prolutex is a water-soluble complex of natural progesterone with hydroxypropyl-β-cyclodextrin (HPBCD), patented as US Patent No. 4,727,064 Pitha, Jallowing for subcutaneous injection.” NCT07350317 ↗ “Group A will be administered subcutaneous progesterone 25 mg/day (Prolutex), and Group B will be administered vaginal progesterone in capsules 200 mg/3 times a day (Progeffik).” NCT02363127 ↗ “subcutaneous progesterone (PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland)” NCT05276531 ↗ “Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone (Progeffik)” NCT03701490 ↗ |
| Known as | Prometrium | “To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be...” NCT01589081 ↗8“Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.” NCT01589068 ↗ “Participants will receive 100 mg per day of Prometrium (oral progesterone) for 13 days.” NCT07620587 ↗ “progesterone (Prometrium)” NCT00361075 ↗ |
| Known as | prontogest | “A total of 137 embryo transfers were randomly allocated into either arm I (67 ) starting luteal support as daily IM injections of 100 mg prontogest on day of egg retrieval , or...” NCT03040830 ↗1“Prontogest 400 mg vaginal suppository contains progesterone 400 mg.” NCT04161989 ↗ |
| Known as | Provera | “One third of patients (twenty) will be randomized to receive adjunctive oral Provera (progesterone) at 20 mg/day.” NCT00206544 ↗ |
| Known as | Psc | “Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4” NCT03740568 ↗ |
| Known as | Seidigestan | “Micronized natural progesterone (Seidigestan(®)) vs GnRH antagonists for preventing the LH surge during controlled ovarian stimulation (PRO_NAT study): study protocol of a...” PMID 38577571 ↗ Mar 2024 |
| Known as | Utrogestan | “Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1...” NCT06497894 ↗16“Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized...” NCT02032797 ↗ “This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT...” NCT06306404 ↗ “for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied” NCT01590173 ↗ “progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.” NCT03637062 ↗ “200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year” NCT01123538 ↗ “Vaginal micronized progesterone (Utrogestan, Besins, Belgium) is started at 200 mg in the afternoon and 200 mg in the evening” NCT06644794 ↗ “Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan” NCT00345306 ↗ “micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily” NCT01269450 ↗ “200 mg daily of vaginal progesterone suppositories (Utrogestan)” NCT02470676 ↗ “micronized progesterone 200 mg 3id (Utrogestan®)” NCT04983173 ↗ |
| Known as | Vasclor | “for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied” NCT01590173 ↗ |
| Action | Inhibit | “Progesterone has been shown to reduce the number of oxytocin receptors in the myometrium and be responsible in the near term pregnant women for blocking the onset of labor.” NCT00830765 ↗ |
| Modality | Other / unclassified | “progesterone (a normal hormone made by the ovaries)” NCT00830765 ↗ |
| Route | Other | “Progesterone suppository, 200mg vaginally twice/day” NCT00001259 ↗ |